Frank Vercruysse

Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trial

Bruce Neal, Vlado Perkovic, Dick de Zeeuw et al. · American Heart Journal · 2013 · 331 citations · Full text

Hypertension, Cardiovascular Pharmacology, Placebo-controlled Trial +17

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial

John Wilding, G. Charpentier, Priscilla Hollander et al. · International Journal of Clinical Practice · 2013 · 314 citations · Full text

Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes

Teresa Quattrin, Michael J. Haller, Andrea K. Steck et al. · New England Journal of Medicine · 2020 · 239 citations

Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium–Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes

Bruce Neal, Vlado Perkovic, Dick de Zeeuw et al. · Diabetes Care · 2014 · 235 citations

Canagliflozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study

Lawrence A. Leiter, Kun‐Ho Yoon, Pablo Arias et al. · Diabetes Care · 2014 · 221 citations · Full text